European Union - English - EMA (European Medicines Agency)

zoetis belgium sa - inactivated bluetongue virus, serotype 1, strain btv-1/alg2006/01 e1 rp, inactivated bluetongue virus, serotype 8, strain btv-8/bel2006/02 - bluetongue virus, immunologicals, immunologicals for bovidae, cattle, inactivated viral vaccines - cattle - active immunisation of cattle from 3 months of age for the prevention* of viraemia caused by bluetongue virus (btv), serotypes 1 and 8.*(cycling value (ct) ≥ 36 by a validated rt-pcr method, indicating no presence of viral genome).

European Union - English - EMA (European Medicines Agency)

zoetis belgium sa - inactivated bluetongue virus, serotype 1, strain btv-1/alg2006/01, inactivated bluetongue virus, serotype 8, strain btv-8/bel2006/02 - bluetongue virus, sheep, inactivated viral vaccines - sheep - active immunisation of sheep from 1.5 months of age to prevent viraemia caused by bluetongue virus, serotypes 1 and 8.onset of immunity: 21 days after completion of the primary vaccination scheme.duration of immunity: 12 months.

European Union - English - EMA (European Medicines Agency)

zoetis belgium sa - one of the following inactivated bluetongue virus strains:inactivated bluetongue virus, serotype 1, strain btv-1/alg2006/01 e1inactivated bluetongue virus, serotype 8, strain btv-8/bel2006/02inactivated bluetongue virus, serotype 4, strain spa-1/2004 - immunologicals, immunologicals for bovidae, inactivated viral vaccines, bluetongue virus, sheep - sheep; cattle - active immunisation of sheep from 6 weeks of age for the prevention of viraemia caused by bluetongue virus, serotypes 1 and 8, and for the reduction of viraemia caused by bluetongue virus, serotype 4 and active immunisation of cattle from 12 weeks of age for the prevention of viraemia caused by bluetongue virus, serotypes 1 and 8.

United Kingdom - English - VMD (Veterinary Medicines Directorate)

zoetis uk limited - bluetongue virus - suspension for injection - inactivated viral vaccine - cattle, sheep

European Union - English - EMA (European Medicines Agency)

zoetis belgium - inactivated bluetongue virus, serotype 8, strain btv-8/bel2006/02 - immunologicals - cattle - active immunisation of cattle from three months of age for the prevention of viraemia caused by bluetongue virus, serotype 8.

European Union - English - EMA (European Medicines Agency)

zoetis belgium sa - inactivated bluetongue virus, serotype 8, strain btv-8/bel2006/02 - immunologicals - sheep - active immunisation of sheep from 1.5 months of age for the prevention of viraemia caused by bluetongue virus, serotype 8.

United States - English - NLM (National Library of Medicine)

teva women's health, inc. - human adenovirus e serotype 4 strain cl-68578 (unii: fkd3duk39i) (human adenovirus e serotype 4 strain cl-68578 - unii:fkd3duk39i) - human adenovirus e serotype 4 strain cl-68578 32000 [tcid_50] - adenovirus type 4 and type 7 vaccine, live, oral is a vaccine indicated for active immunization for the prevention of febrile acute respiratory disease caused by adenovirus type 4 and type 7. adenovirus type 4 and type 7 vaccine, live, oral is approved for use in military populations 17 through 50 years of age. adenovirus type 4 and type 7 vaccine, live, oral should not be administered to pregnant females [see pregnancy (8.1)] . it is not known whether adenovirus type 4 and type 7 vaccine, live, oral can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. naturally occurring infection with adenoviruses has been associated with fetal harm. pregnancy should be avoided for 6 weeks following receipt of vaccine. severe allergic reaction (e.g., anaphylaxis) to any component of adenovirus type 4 and type 7 vaccine, live, oral is a contraindication [see description (11)]. adenovirus type 4 and type 7 vaccine, live, oral should not be administered to individuals incapable of swa

European Union - English - EMA (European Medicines Agency)

mérial - bluetongue-virus serotype-2 antigen, bluetongue-virus serotype-4 antigen - bluetongue virus, inactivated viral vaccines, immunologicals for ovidae - sheep - active immunisation of sheep to prevent viraemia and to reduce clinical signs caused by bluetongue virus serotypes 2 and 4.

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - bluetongue-virus serotype-1 antigen, bluetongue virus serotype 8 antigen - immunologicals - sheep; cattle - sheepactive immunisation of sheep and cattle to prevent viraemia and to reduce clinical signs caused by bluetongue virus serotypes 1, 2, 4 and/ or 8 (combination of maximum 2 serotypes), active immunisation of sheep and cattle to prevent viraemia and to reduce clinical signs caused by bluetongue virus serotypes 1,2, 4 and/ or 8 (combination of maximum 2 serotypes), active immunisation of sheep to prevent viraemia and to reduce clinical signs caused by bluetongue virus serotypes 1, 2, 4 and/or 8 (combination of maximum 2 serotypes).cattleactive immunisation of cattle to prevent viraemia caused by bluetongue virus serotype 1, 2, 4 and/ or 8, and to reduce clinical signs caused by bluetongue virus serotypes when observed in this species: serotype 1, 4 and / or 8 (combination of maximum 2 serotypes).active immunisation of cattle to prevent viraemia caused by bluetongue virus serotype 1, 2, 4 and/ or 8, and to reduce clinical signs caused by bluetongue virus serotypes when observed in this species: serotype 1, 4 and / or 8 (combination of maximum 2 serotypes).active immunisation of sheep and cattle to prevent viraemia and to reduce clinical signs caused by bluetongue virus serotypes 1, 2, 4 and/or 8 (combination of maximum 2 serotypes).

European Union - English - EMA (European Medicines Agency)

merial - bluetongue-virus serotype-1 antigen - immunologicals - sheep; cattle - active immunisation of sheep and cattle to prevent viraemia and to reduce clinical signs caused by bluetongue virus serotype 1.onset of immunity has been demonstrated three weeks after the primary vaccination course. the duration of immunity for cattle and sheep is one year after the primary vaccination course.